H e alth his to r y. Chapter 3 Health history. s29
|
|
- Noreen Waters
- 5 years ago
- Views:
Transcription
1 3 H e alth his to r y My mama died from undetected kidney disease in Oct. 22. It was only after 2 years of being treated for high blood pressure, a blood test [was done] to check on her kidneys. She went on dialysis but died a few months later. That s why I got involved and got screened. Thank you for coming and helping us! Participant: Screening date, December, 25 d i a b e t e s h y p e r t e n s i o n c a r d i o v a s c u l a r d i s e a s e o b e s i t y s m o k i n g e v i d e n c e o f k i d n e y d i s e a s e f a m i l y h i s t o r y & c o m o r b i d i t y i n t e r v e n t i o n Chapter 3 Health history s29
2 t i i t i t l f t diabetes e d D M - r e p o r h s e P e r c e n t w Age Gender Race/ethnicity NHANES 99-2 All Male Female White Black Other Hisp s n a p c r a f p t o n i t t e l he program s primary focus is the early detection of CKD in individuals a known history of diabetes or hypertension, or a family history of diabetes, hypertension, or kidney disease. Over 25% of eligible participants report having diabetes or diabetic retinopathy. Rates are highest in older participants. Of the participants who report having diabetes, 38% are prehypertensive, based on criteria from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7); the percent self-reported diabetes increases the severity of hypertension. 3.1 Self-reported diabetes in & NHANES participants, by age, gender, & race/ethnicity c r e P N= 55,22, age & Hispanics; 55,143, gender; 54,11, race. NHANES N= 11, Diabetic Non-diabetic NHANES 99-2 Forty-eight percent of participants who report having diabetes were fund to have an elevated blood sugar, defined as a fasting glucose greater than 126 mg/dl or a non-fasting glucose exceeding 139 mg/dl. 3.2 Normal Pre HTN Stage 1 Stage 2 Normal Pre HTN Stage 1 Stage 2 Blood pressure stages (JNC 7) in & NHANES participants, by self-reported diabetic status N= 53,785. NHANES N= 1,89. Elevated blood pressure is more pronounced in black and NHANES participants compared to whites and people of other races, regardless of diabetic status. Elevated blood pressure occurs in 71 and 33%, respectively, of Hispanic participants and out diabetes. e d B P e v a h e P e r c e n t w 1 Diabetic White Black OtherHispanic Male Female Non-diabetic NHANES 99-2 White Black OtherHispanic Male Female A measured glucose greater than the normal limit is nearly eight times more evident in participants who report having diabetes than in those who report no diabetes. 3.3 Elevated blood pressure (JNC 7) in & NHANES participants, by race/ethnicity, gender, & self-reported diabetic status N= 54,35, gender; 53,182, race. NHANES N= 9,421. s3 National Kidney Foundation Kidney Early Evaluation Program 26
3 self-reported DM NHANES Normal Prehypertension Stage 1 Stage Self-reported diabetes in & NHANES participants, by blood pressure stage (JNC 7) N= 54,32. NHANES N= 1,89. glucose > NL Age Gender Race/ethnicity Self-reported DM No self-reported DM All Male Female White Black Other Hisp 3.5 Measured glucose > normal limit in participants, by age, gender, race/ethnicity, & self-reported diabetic status N= 53,217, age & Hispanic; 53,152, gender; 52,95, race. diabetes SR : Age Race/ethnicity NHANES 99-2: Age Race/ethnicity * * * * White Black Other Hispanic * * * 3.6 of & NHANES participants self-reported diabetes, by education & insurance status, age, & race/ethnicity N= 51,954, age & Hispanics; 5,952, race. NHANES N= 11,165. *Sample size less than 3 or coefficient of variation not less than 3%. Chapter 3 Health history s31
4 hypertension HTN self-reported Age Gender Race/ethnicity NHANES All Self-reported hypertension in & NHANES participants, by age, gender, & race/ethnicity N= 54,56, age & Hispanics; 54,433, gender; 53,353, race. NHANES N= 11,271. Male Female White Black Other Hisp glucose > than NL NHANES 99-2 Self-rep. HTN No self-rep.htn Measured glucose greater than the normal limit in and NHANES participants, by self-reported hypertension N= 53,62. NHANES N= 9,717. elevated glucose 3 2 Self-reported HTN No self-reported HTN NHANES White Black OtherHispanic Male Female White Black OtherHispanic Male Female 3.9 Measured glucose greater than the normal limit in & NHANES participants, by gender, race/ethnicity, & self-reported hypertension status N= 51,956 race; 52,997, gender. NHANES N= 9,717. ver 52% of participants report having hypertension, compared to one-quarter of individuals in the general population. Proportions of participants self-reported hypertension increase age, are comparable in males and females, and are slightly higher in blacks compared to whites, individuals of other races, and Hispanics. Elevated blood glucose a measure glucose greater than the normal limit is more evident in participants who report having hypertension compared to those not reporting the condition, and is s32 National Kidney Foundation Kidney Early Evaluation Program 26
5 HTN self-reported NHANES Normal glucose Glucose >NL Self-reported hypertension in and NHANES participants, by glucose level N= 53,62. NHANES N= 9,717. BP Stage Age Gender Race/ethnicity Self-reported HTN No self-reported HTN All Male Female White Black Other Hispanic Measured blood pressure Stage 1 hypertension (JNC 7), in participants, by age, gender, race/ethnicity, & self-reported hypertension N= 53,623, age; 53,554, gender; 52,485 race. SR hypertension 1 : Age Race/ethnicity White NHANES 99-2: Age Race/ethnicity Black 61+ Other 6 Hispanic Self-reported hypertension in & NHANES participants, by education & insurance status, age, & race/ethnicity N= 51,796, age; 5,88, race. NHANES N= 9,717. *Sample size less than 3 or coefficient of variation not less than 3%. * most prominent in males and individuals of other races. The percent of participants a measured blood pressure greater than Stage 1 (JNC 7) is four times higher in those who report being hypertensive, increases age, and is highest in blacks, at 25.2%, compared to 2, 17.3, and 18.2%, respectively, in whites, individuals of other races, and Hispanics. In both the and NHANES populations, and across all age and race/ethnicity groups, rates of self-reported hypertension are highest in participants less than a high school education. Chapter 3 Health history s33
6 cardiovascular disease % cardiovascular disease Age All Gender Race/ethnicity Male Female White Black Other Hispanic 3.13 Cardiovascular disease in participants, by age, gender, & race/ethnicity N= 54,173, age; 54,111, gender; 53,3, race. % cardiovascular disease Age CKD No CKD All Gender Race/ethnicity Male Female White Black Other Hispanic 3.14 Cardiovascular disease in participants & out CKD, by age, gender, & race/ethnicity N= 45,311 age & gender; 44,4, race. early 18% of participants report a history of cardiovascular disease (CVD), including a heart attack, bypass surgery, angioplasty, stroke, heart failure, peripheral vascular disease, or arrhythmia. Rates are most pronounced in older participants, and reach 35% in those age 75 and older. Twenty percent of white participants report having CVD, compared to 17, 15.5, and 15.1%, respectively, of blacks, individuals of other races, and Hispanics. Nearly 27% of participants CKD report a diagnosis of CVD, compared to 15% in those out the disease. By race/ethnicity, rates of CVD are 1 13% higher in participants CKD compared to those not having the diagnosis. The most common risk factor for cardiovascular disease reported by participants CKD is an elevated blood pressure nearly 77% of participants cardiovascular disease have associated elevated blood pressure. Rates of cardiovascular disease are highest in participants who have less than a high school education. s34 National Kidney Foundation Kidney Early Evaluation Program 26
7 risk factor With cardiovascular disease CKD No CKD SRDM BMI 3 Elv BP Hist of Smoking WHO Anemia Without cardiovascular disease SRDM BMI 3 Elv BP Hist of Smoking WHO Anemia 3.15 Reported risk factors in participants & out cardiovascular disease N= 41,354. disease cardiovascular : Age Race/ethnicity NHANES 99-2: Age Race/ethnicity White Black Other Hispanic of & NHANES participants cardiovascular disease, by education & insurance status, age, & race/ethnicity N=52,398, age; 51,381, race. NHANES N= 9,99, participants age 2 and older. *Sample size less than 3 or coefficient of variation not less than 3%. * * * * * * * * * * Chapter 3 Health history s35
8 obesity NHANES 99-2 OW: 32.9 N: 21.7 UW:.8 N: 33.6 UW: 2. EO: 8.8 OW: 34.2 EOB: 4.9 OB: 35.8 OB: distribution of & NHANES participants, by BMI category N= 54,466. NHANES N= 1,132. participants NHANES 99-2 Underweight Normal Overweight Obese Extremely obese of 2 1 Male Female Male Female 3.18 BMI in & NHANES participants, by gender & BMI category N= 54,396. NHANES N=1,132. participants 6 4 NHANES 99-2 Underweight Normal Overweight Obese Extremely obese participants 5 Underweight Normal 4 Overweight 3 Obese Extremely obese of 2 of 2 1 White Black Other Hispanic White Black Other Hispanic Northeast Midwest South West 3.19 BMI in & NHANES participants, by race/ethnicity N= 53,292. NHANES N=1, BMI in participants, by U.S. Census Region N= 54,446. s36 National Kidney Foundation Kidney Early Evaluation Program 26
9 % self-reported DM or HTN NHANES 99-2 Diabetes Hypertension * UW N OW OB EOB Diabetes Hypertension of participants NHANES 99-2 BMI<25 (kg/m 2 ) BMI 25-<3 (kg/m 2 ) BMI 3+ (kg/m 2 ) NormalPre HTNStage 1 Stage 2 NormalPre HTNStage 1 Stage & NHANES participants self-reported diabetes or hypertension, by BMI category N= 53,321; NHANES N= 1,127, diabetes; 9,998, hypertension. *Sample size less than 3 or coefficient of variation not less than 3% BMI in & NHANES participants, by measured blood pressure (JNC 7) N= 53,626. NHANES N= 9,781. BMI 3 kg/m : Age Race/ethnicity NHANES 99-2: Age Race/ethnicity White Black Other Hispanic of & NHANES participants a BMI 3 kg/m 2, by age, race/ethnicity, education, & insurance status N= 51,723, age; 5,732, race. NHANES N= 9,959. ver three-fourths of participants are classified as being overweight to extremely obese, compared to a 64% rate in the general population. Of eligible participants, 8% of males and 76% of females are, at the least, overweight, and females have a higher rate of overall obesity than males, at 47 and 4%, respectively. By race/ethnicity, over 4% of black participants are classified as obese and 12% are extremely obese, compared to 33.3 and 7.3% of whites. By Census region, the percent of participants who are obese to extremely obese ranges from 39% in the West to 48% in the Midwest. Obesity is more evident in participants selfreported hypertension compared to those selfreported diabetes 61.1% compared to 31.3%, while 56% of participants diagnosed Stage 2 hypertension (JNC 7) have a BMI equal to or exceeding 3 kg/m 2. Irrespective of insurance and educational status, the highest rates of obesity are generally found in participants age 46 6, and black participants are more prone to this condition. Chapter 3 Health history s37
10 smoking history patients of NHANES 99-2 Smoking Used to smoke Never smoked 3.24 distribution of & NHANES participants, by smoking status N= 51,88. NHANES N= 1,261. of participants NHANES 99-2 Never smoked Used to smoke Smoking White Black Other Hispanic White Black Other Hispanic 3.25 Smoking status in & NHANES participants, by race/ethnicity N= 5,726. NHANES N= 1,261. self-reported DM NHANES Smoking Used to smoke Never smoked 3.26 Self-reported diabetes in & NHANES participants, by smoking status N= 51,336. NHANES N=1,258, participants age 2 and older. s38 National Kidney Foundation Kidney Early Evaluation Program 26
11 self-reported HTN NHANES 99-2 CKD NHANES 99-2 Smoking Used to smoke Never smoked Smoking Used to smoke Never smoked 3.27 Self-reported hypertension in & NHANES participants, by smoking status N= 51,181. NHANES N= 1,137, participants age 2 and older CKD in & NHANES participants, by smoking status N= 42,571. NHANES N= 8,7. smoking history : Age Race/ethnicity NHANES 99-2: Age Race/ethnicity White Black Other Hispanic 3.29 & NHANES participants a history of smoking, by education & insurance status, age, & race/ethnicity N= 48,92. NHANES N= 1,45. hirteen percent of participants report that they currently smoke, compared to 25% of the general population. Nearly 3% used to smoke, and 57.4% report never having smoked. In the population, smoking is most common in individuals of other races. Almost 31% of those who used to smoke report having diabetes, compared to 24% who never smoked and 22% who currently smoke. Close to 6% of participants who used to smoke report being hypertensive, compared to 51% who never smoked and 46% who currently smoke. One-third of eligible participants who used to smoke report a diagnosis of CKD, in comparison to 28% of those who never smoked, and 24% who currently smoke. In both the and NHANES populations, the percent of participants a history of smoking is greatest in those less than a high school education. Chapter 3 Health history s39
12 evidence of kidney disease condition Number condition 5, 4, 3, 2, 1, Total in category 15 in category Kidney disease Kidney stones 12 Kidney dis./stones 9 condition 6 3 Kidney disease Kidney stone Both All Male Female All Male Female 3.3 Self-reported kidney problems in participants N= 53, Self-reported kidney problems in participants, by gender N= 53,489. condition 5, 4, 3, Total in category Kidney disease Kidney stones Both condition in category condition 5, 4, 3, Total in category Kidney disease Kidney stones Both condition in category Number 2, 1, 6 3 Number 2, 1, 6 3 All White Black Hispanic Other All White Black Hispanic Other All NE MW S W All NE MW S W 3.32 Self-reported kidney problems in participants, by race/ethnicity N= 52, Self-reported kidney problems in participants, by U.S. Census Region N= 53,526. f eligible participants, more than 4,1 report having kidney stones (8.%), while 2.2% report having kidney problems. Kidney stones are more common in males than in females. Eleven percent of white participants report kidney stones, compared to 4, 7, and 7.6%, respectively, of blacks, individuals of other races, and Hispanics. Kidney stones are reported by 8.% of participants living in the South and West, 7.4% in the Northeast, and 6.5% in the Midwest. In the population, 13.5% of whites are classified as having Stage 2 CKD. Stage 2 CKD is evenly distributed in blacks, people of other races, and Hispanics, ranging form %. In NHANES participants, Stage 3 CKD is more prominent in whites, at 2.1%, followed by blacks, individuals of other races, and Hispanics, at 15.5, 14., and 12.%, respectively. s4 National Kidney Foundation Kidney Early Evaluation Program 26
13 8 6 Stage 1 Stage 2 Stage 3 Stages participants of NHANES * * All White Black Other Hispanic 3.34 CKD in & NHANES participants, by CKD stage & race/ethnicity N= 12,7, NHANES N= 1,55. *Sample size less than 3 or coefficient of variation not less than 3%. CKD : Age Race/ethnicity NHANES 99-2: Age Race/ethnicity White Black Other Hispanic * * 3.35 CKD in & NHANES participants, by education & insurance status, age, & race/ethnicity N= 43,8, age; 42,24, race. NHANES N=9,567. *Sample size less than 3 or coefficient of variation not less than 3%. Chapter 3 Health history s41
14 family history & comorbidity 6 CKD Diabetes (SR) HTN (SR) Obesity Smoking risk factor Northeast Midwest South West 3.36 Risk factors in participants, by U.S. Census Region Across all U.S. Census Regions, hypertension is the most commonly reported risk factor for participants, ranging from %. N= 41, DM (family history) family history HTN (family history) KD (family history) Self-rep DM Self-rep NDM 3.37 Family history of diabetes, hypertension, or kidney disease in participants, by self-reported diabetic status N= 5,381. n participants, hypertension is the most commonly reported risk factor in all U.S. Census Regions, ranging from 47.4% in the West to 55.4% in the South. Proportions of diabetes are similar across all regions, ranging from %, and approaching 3% in participants CKD. Eighty-two percent of participants who report no diabetes have a family history of hypertension; in those self-reported diabetes, a family history of hypertension is evident in 74%. The percent of participants a family history of either diabetes, hypertension, or kidney disease does not appear to be related to the severity of hypertension and participant family members are more likely than participants to experience a cardiac event. Two-thirds of participants Stage 1 (JNC 7) hypertension report a family history of diabetes, and 8% report a family history of hypertension. And participant family members are far more likely than participants to have undergone a cardiac procedure or have experienced a cardiac event. s42 National Kidney Foundation Kidney Early Evaluation Program 26
15 family history DM (fam. history) HTN (fam. history) KD (fam. history) Normal Prehypertension Stage 1 Stage Family history of diabetes, hypertension, or kidney disease in participants, by measured blood pressure (JNC 7) N= 49,994. cardiac event Family member Participant family history DM (fam. history) HTN (fam. history) KD (fam. history) 1 HA BPS Angio Stroke HF Arrhyth PVD 2 Normal Stage 1 Stage 2 Stage 3 Stage participants a family member who has had a cardiac event & who have suffered the same cardiac event as a family member N= 53,76, heart attack; 1,117, heart bypass surgery; 1,22, heart angioplasty; 53,651, stroke; 1,7, heart failure; 1,94, arrhythmia; 55,22, PVD. family member N= 52,281, heart attack; 7,95, heart bypass surgery; 51,881, stroke; 7,535, heart failure; 7,24 arrhythmia; 55,22, PVD. 3.4 Family history of diabetes, hypertension, or kidney disease in participants, by CKD stage N= 41,643. Chapter 3 Health history s43
16 intervention % of completing followup form All returning followup form Yes No NA 3.41 participants who complete their followup forms, by year N= 16, participants who return their followup forms, by seeing a physician N= 16,194. who saw a physician BP Glucose Urine CR CCR Hgb Oth Other reasons Not recommended I have no time No insurance I don't believe it is necessary Cannot afford No physician 3.43 Reason for seeing a physician about test results among participants who return their followup forms N= 1,889. Not able to get to appt Don't know Cannot take time off MD said not necessary 3.44 No transportation of participants Reasons why participants do not see a physician after receiving abnormal test results N=4,758. s44 National Kidney Foundation Kidney Early Evaluation Program 26
17 medical intervention OTC medications Prescription Injection Other 3.45 participants who learn they have anemia, & have a medical intervention N= 352. medical intervention Monitor BS Diet adjust. Drug therapy Insulin Other medical intervention Monitored BP Diet adjust. Drug therapy Other 3.46 participants who learn they have diabetes, & have a medical intervention N= 1, participants who learn they have high blood pressure, & have a medical intervention N= 2,248. ntervention following the evaluation is an integral part of the program. On their study followup forms, 67% of participants report seeing a physician after the study. Of these individuals, 5% have seen a physician because of abnormal blood pressure results, while 46.8% have consulted a physician because of an abnormal urine test. For a variety of reasons, some participants do not see a physician after receiving notification of an abnormal test; of these, 12.5% report having no insurance while 12% do not believe the visit is necessary. In participants who learn they have anemia, 32% are placed on over-thecounter medications and 2% receive a prescription drug. Forty-two percent of participants who learn they have diabetes are told to monitor their blood sugar, while 39% undergo drug therapy; in participants who learn they have high blood pressure, 42.6% are told to monitor their blood pressure, and 47% are placed on prescription drugs. Chapter 3 Health history s45
18 chapter highlights Figure 3.1 Over 25% of eligible participants report having diabetes or diabetic retinopathy. Rates are highest in older participants. Figure 3.4 The percent self-reported diabetes increases the severity of hypertension. Figure 3.7 Proportions of participants self-reported hypertension increase age, are comparable in males and females, and are slightly higher in blacks compared to whites, individuals of other races, and Hispanics. Figure 3.1 The proportion of and NHANES participants who report having hypertension is greatest in those an elevated glucose. Figure 3.13 Nearly 18% of participants report a history of cardiovascular disease. Figure 3.17 Over three-fourths of participants are classified as being overweight to extremely obese, compared to a 64% rate in the general population. Figure 3.24 Thirteen percent of participants report that they currently smoke, compared to 25% of the general population. Nearly 3% used to smoke, and 57.4% report never having smoked. Figure 3.42 On their study followup forms, 67% of participants report seeing a physician after the study. JNC 7 Hypertension Normal systolic <12 mmhg & diastolic <8 mmhg Prehypertension systolic mmhg or diastolic 8-89 mmhg Stage 1 systolic mmhg or diastolic 9-99 mmhg Stage 2 systolic 16 mmhg or diastolic 1 mmhg Elevated blood pressure (EBP) (JNC 7) DM or CKD: systolic: 13 mmhg or diastolic: 8 mmhg No DM or CKD: systolic: 14 mmhg or diastolic: 9 mm Hg Diabetes Self-reported diabetes Elevated blood sugar Glucose greater than the normal limit Fasting: >126 mg/dl Non-fasting: >139 mg/dl Risk factors for Cardiovascular disease Diabetes BMI 3 kg/m 2 Smoking history Anemia (WHO definition) Elevated blood pressure CVD definition: Participant reporting any of the following cardiac events: heart attack, heart by-pass surgery, heart angioplasty, stroke, heart failure, stroke, PVD, or arrhythmia CVD definition (NHANES) Participant reporting any of the following cardiac diseases: congestive heart failure, coronary heart disease, angina/angina pectoris, heart attack, or stroke CKD Definition If egfr by K/DOQI MDRD <6 ml/min/1.73 m 2 or egfr 6 ml/min/1.73 m 2 and abnormal albumin/creatinine ratio (ACR 3mg/g) CKD Stages Stage 1: egfr 9, ACR 3 mg/g Stage 2: egfr 6 89, ACR 3 mg/g Stage 3: egfr 3 59 Stage 4: egfr Stage 5: egfr <15 or dialysis U.S. Census Regions NE: Northeast MW: Midwest S: South W: West Body Mass Index Categories UW: underweight, BMI <18.5 N: normal, BMI OW: overweight, BMI OB: obese, BMI EOB: extremely obese, BMI 4 Education & insurance <HS&NIns: Less than a high school education, & no insurance <HS&Ins: Less than a high school education, & insurance HS+&NIns: High school education or greater, & no insurance HS+&Ins: High school education or greater, & insurance Cardia Event definitions HA: Heart Attack BPS: Heart by-pass surgery Angio: Angioplasty HF: Heart failure Arrhyth: Arrhythmia PVD: Peripheral vascular disease s46 National Kidney Foundation Kidney Early Evaluation Program 26
KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64
211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated
More informationKEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.
28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,
More informationKEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56
21 Summary Figures S32 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar
More informationKEEP 2009 Summary Figures
S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationKEEP 2.0 Annual Data Report Chapter Five
KEEP 2. Annual Data Report Chapter Five Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants 12 8 4 All
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationKEEP 2005 Annual Data Report
KEEP 25 Annual Data Report The National Kidney Foundation gratefully acknowledges the support of our primary sponsor and our associate sponsor Additional thanks to Bayer Diagnostics, Satellite Healthcare,
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationKidney Early Evaluation Program KEEP. A n n u a l D a t a R e p o r t
Kidney Early Evaluation Program KEEP A n n u a l D a t a R e p o r t The National Kidney Foundation gratefully acknowledges the support of our primary sponsor and our associate sponsors Additional thanks
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationAs evidenced by a recent analysis of National
The Kidney Early Evaluation Program (KEEP): Program Design and Demographic Characteristics of the Population Claudine T. Jurkovitz, MD, MPH, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 David T. Gilbertson,
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationEXECUTIVE SUMMARY S3. ONE Program Introduction S5. TWO Participant Characteristics S16. THREE Obesity & Body Mass Index S28
KEEP EXECUTIVE SUMMARY S3 ONE Program Introduction S5 TWO Participant Characteristics S16 THREE Obesity & Body Mass Index S28 FOUR Major Risk Factors for Chronic Kidney Disease S34 FIVE Chronic Kidney
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population In light of the 2017 blood pressure guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), this year we examine hypertension control
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationDiabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES)
Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004 Adam T. Whaley-Connell, DO, MSPH, 1 James R. Sowers, MD, 1 Samy
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationICD-10CM, HCC and Risk Adjustment Factor
ICD-10CM, HCC and Risk Adjustment Factor Not everyone is aware of what CMs calls the risk adjustment model. It was developed under the Patient Protection and Affordable Care Act (also known as the PACA)
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationThe Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine
The Heart of a Woman Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine American Heart Association Women, Heart Disease and Stroke
More informationCHRONIC DISEASE PREVALENCE AMONG ADULTS IN OHIO
OHIO MEDICAID ASSESSMENT SURVEY 2012 Taking the pulse of health in Ohio CHRONIC DISEASE PREVALENCE AMONG ADULTS IN OHIO Amy Ferketich, PhD Ling Wang, MPH The Ohio State University College of Public Health
More informationckd data sources 2013 USRDS annual data report data sources volume one
138 140 140 140 141 data sources database definitions identification of major comorbidities ckd in the general population chapter one identification & care of ckd patients chapter two 142 hospitalization
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPut your Heart before your Head
Put your Heart before your Head Alok K Gupta, MD, FAAFP, FASH Associate Professor, Outpatient Clinic since 1963, the US Congress has required the President to proclaim February "American Heart Month."
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationThe incidence and prevalence of hypertension
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationAshberyh CHAPTER. John
A knowledge that people live close by is, I think, enough. And even if only first names are ever exchanged The people who own them seem rock-true and marvelously self-suficient. John Ashberyh The Ongoing
More informationCARE PATHWAYS. Allyson Ashley
CARE PATHWAYS Allyson Ashley WHAT IS A CARE PATHWAY? An explicit statement of the goals and key elements of care based on evidence, best practice, and patient s expectations and their characteristics The
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationKnow Your Numbers. Your guide to maintaining good health. Helpful information from Providence Medical Center and Saint John Hospital
Know Your Numbers Your guide to maintaining good health Helpful information from Providence Medical Center and Saint John Hospital If it has been awhile since your last check up and you are searching for
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSection 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationPatient is healthy with no chronic disease or significant risk factors [16%].
AAFP Risk Level 1 Patient is healthy with no chronic disease or significant risk factors [16%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationTwo: Chronic kidney disease identified in the claims data. Chapter
Two: Chronic kidney disease identified in the claims data Though leaves are many, the root is one; Through all the lying days of my youth swayed my leaves and flowers in the sun; Now may wither into the
More informationClinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria
Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationHypertension AN OVERVIEW
AN OVERVIEW Hypertension Your doctor has determined that you have high blood pressure, or hypertension. Although high blood pressure is never really cured, it can be controlled by early detection, lifestyle
More informationMetabolic Syndrome: A Preventable & Treatable Cluster of Conditions
Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions April D. McNeill MD Candidate 2016, Southern Illinois University, School of Medicine GE-NMF Primary Care Leadership Program, July 2013
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More information2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST
CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationFructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationFULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access
INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationReport Operation Heart to Heart
Report Operation Heart to Heart Elkhorn Logan Valley Public Health Department (Burt, Cuming, Madison, and Stanton Counties) Gina Uhing, Health Director Ionia Research Newcastle, Nebraska Joseph Nitzke
More information